Rare diseases
Investigational molecules
Locations
Ul. Alfreda Sokolowskiego 4, 58-309 Walbrzych, Poland
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego in Walbrzych, Poland specialises in clinical trials of conditions such as Plasma cell myeloma, Acute myeloid leukaemia, Myelofibrosis, Non-small cell lung cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of cardiology research, particularly focusing on heart failure and myocardial infarction. The ongoing studies aim to improve outcomes for patients with reduced left ventricular ejection fraction following myocardial infarction.
Through innovative therapies, the center is enhancing the standard of care for heart failure patients, contributing significantly to the field of cardiovascular medicine.
Specializing in hematology, the center conducts advanced research on diffuse large B-cell lymphoma, focusing on relapsed or refractory cases. The integration of novel therapeutic agents with standard care regimens is a key area of exploration.
By evaluating new drug combinations, the center aims to improve progression-free survival rates, offering hope to patients with challenging lymphoma cases.
The center is pioneering research in oncology, with a focus on myelofibrosis. Studies are underway to assess the efficacy of combining selective inhibitors with existing treatments, aiming to enhance patient outcomes.
These efforts are crucial in developing more effective treatment protocols for myelofibrosis, potentially transforming the therapeutic landscape for this condition.
In the realm of chronic lymphocytic leukemia, the center is conducting pivotal trials to compare the efficacy of different drug combinations in newly diagnosed patients. This research is vital for optimizing first-line treatment strategies.
By evaluating novel therapeutic combinations, the center is contributing to the development of more effective and safer treatment options for leukemia patients.
Focusing on multiple myeloma, the center is investigating alternative dosing regimens of innovative therapies to manage relapsed or refractory cases. This research is crucial for minimizing adverse effects while maintaining efficacy.
Through these studies, the center aims to refine treatment protocols, enhancing the quality of life for multiple myeloma patients.
The center is advancing research in myelodysplastic syndromes, focusing on achieving red blood cell transfusion independence in lower-risk patients. This work is pivotal in improving anemia management in these individuals.
By exploring new therapeutic approaches, the center is making significant strides in the treatment of myelodysplastic syndromes, offering new hope to patients.
Specializing in vasculitis, the center is evaluating the long-term safety and efficacy of novel treatments for ANCA-associated vasculitis. This research is essential for developing safer, more effective therapies for autoimmune conditions.
Through these studies, the center is enhancing the understanding and management of autoimmune disorders, contributing to improved patient care.
Clinical trials currently enrolling participants at this site.
PolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
